Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Arvinas Inc | ARVN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 29.12 | 03:09:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 29.12 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 13.57 - 53.08 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 29.12 | USD |
Arvinas Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.98B | 68.08M | - | 78.5M | -367.3M | -5.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arvinas News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARVN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 34.57 | 35.34 | 27.595 | 30.32 | 974,575 | -5.45 | -15.77% |
| 1 Month | 34.33 | 37.38 | 27.595 | 32.52 | 788,515 | -5.21 | -15.18% |
| 3 Months | 45.08 | 46.51 | 27.595 | 36.03 | 739,957 | -15.96 | -35.40% |
| 6 Months | 23.91 | 53.08 | 22.34 | 38.70 | 809,800 | 5.21 | 21.79% |
| 1 Year | 23.17 | 53.08 | 13.57 | 32.61 | 643,265 | 5.95 | 25.68% |
| 3 Years | 71.12 | 108.465 | 13.57 | 46.32 | 516,558 | -42.00 | -59.06% |
| 5 Years | 20.87 | 108.465 | 13.57 | 46.63 | 502,872 | 8.25 | 39.53% |
Arvinas Description
| Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
